Could BTK Inhibitors Be the Next Big MS Treatment?

Could BTK Inhibitors Be the Next Big MS Treatment?

301369

Could BTK Inhibitors Be the Next Big MS Treatment?

Is orelabrutinib one of the next big MS therapies? Biogen is betting at least $125 million that it is. Orelabrutinib is an experimental oral BTK inhibitor (BTKi). BTKi’s are designed to selectively block an enzyme that’s important for the activation of B-cells and microglia. Some of those immune cells drive the abnormal immune responses that characterize MS. Researchers hope the medication will lower inflammation and slow progression of all forms of MS, as Multiple Sclerosis…

You must be logged in to read/download the full post.